| Identification | Back Directory | [Name]
plafibride | [CAS]
63394-05-8 | [Synonyms]
Idonor
ITA-104
Perifunal
plafibride
Brn 0569805
Einecs 264-121-2
N-2(p-Chlorophenoxy)isobutyryl-N'-morpholinomethylurea
N-(2-(4-Chlorophenoxy)isobutyryl)-N-morpholinomethylurea
N'-Morpholinomethylurea, N-2-(p-chlorophenoxy)isobutyryl-
N-2(p-Chlorophenoxy)-2-methylpropionyl-N'-morpholinomethylurea
1-(2-(p-Chlorophenoxy)-2-methylpropionyl)-3-(morpholinomethyl)urea
1-[2-(4-Chlorophenoxy)-2-methylpropionyl]-3-(morpholinomethyl)urea
2-(4-Chlorophenoxy)-2-methyl-N-[[(4-morpholinylmethyl)amino]carbonyl]propanamide
Propanamide, 2-(4-chlorophenoxy)-2-methyl-N-[[(4-morpholinylmethyl)amino]carbonyl]- | [EINECS(EC#)]
264-121-2 | [Molecular Formula]
C16H22ClN3O4 | [MDL Number]
MFCD00866795 | [MOL File]
63394-05-8.mol | [Molecular Weight]
355.82 |
| Hazard Information | Back Directory | [Uses]
Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor[1][2]. | [Definition]
ChEBI: Plafibride is an aromatic ether. | [in vivo]
Plafibride (100 mg/kg, p.o.) shows marked platelet anti-aggregant activity[1].
Plafibride has low toxicity, with LD50s of about 4000 mg/kg (p.o.) in rat, mouse and hamster[2].
| Animal Model: | Rabbit[1] | | Dosage: | 100 mg/kg | | Administration: | Oral administration (p.o.) | | Result: | Induced platelet aggregation.
|
| [References]
[1] L Bruseghini, et al. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit. Arzneimittelforschung. 1981;31(10a):1790-5. PMID:6797443
[2] J Zapatero, et al. Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride. Arzneimittelforschung. 1981;31(10a):1816-9. PMID:7198458 |
|
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
http://m.approvedhomemanagement.com/ShowSupplierProductsList694812/0.htm |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|